Janet Hopkins
Hoofd Techniek/Wetenschap/O&O bij AURA BIOSCIENCES, INC.
Vermogen: 1 M $ op 30-04-2024
Actieve functies van Janet Hopkins
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
GYROSCOPE THERAPEUTICS HOLDINGS PLC | Directeur/Bestuurslid | 17-02-2022 | - |
AURA BIOSCIENCES, INC. | Hoofd Techniek/Wetenschap/O&O | 16-10-2023 | - |
Loopbaan van Janet Hopkins
Eerdere bekende functies van Janet Hopkins
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
NOVARTIS AG | Corporate Officer/Principal | 01-11-2021 | 01-10-2023 |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Algemeen Directeur | 01-12-2021 | 01-10-2023 |
Opleiding van Janet Hopkins
McMaster University | Doctorate Degree |
Statistieken
Internationaal
Verenigd Koninkrijk | 3 |
Verenigde Staten | 2 |
Zwitserland | 2 |
Operationeel
Director/Board Member | 1 |
Chief Tech/Sci/R&D Officer | 1 |
Corporate Officer/Principal | 1 |
Sectoraal
Health Technology | 5 |
Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
AURA BIOSCIENCES, INC. | Health Technology |
NOVARTIS AG | Health Technology |
Bedrijven in privébezit | 2 |
---|---|
Gyroscope Therapeutics Holdings Plc
Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
Gyroscope Therapeutics Ltd.
Gyroscope Therapeutics Ltd. BiotechnologyHealth Technology Gyroscope Therapeutics Ltd. operates as an ophthalmology firm. It develops a cutting edge, genetically-defined therapies for the treatment of eye diseases linked to an unbalanced complement system. The company was founded on April 18, 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Beurs
- Insiders
- Janet Hopkins
- Ervaring